Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.

Michael LattanziJoseph HanUna MoranKierstin UtterJeremy TchackRachel Lubong SabadoRussell BermanRichard ShapiroHsin-Hui HuangIman OsmanNina BhardwajAnna C Pavlick

Published in: Journal for immunotherapy of cancer (2018)

In this small retrospective cohort of resected stage III melanoma patients, adjuvant NY-ESO-1 vaccine immunotherapy was associated with longer recurrence-free and overall survival relative to historical controls. These data support the continued investigation of adjuvant NY-ESO-1 based immunotherapy regimens in melanoma.

Keyphrases

early stage
prognostic factors
end stage renal disease
lymph node
skin cancer
chronic kidney disease
newly diagnosed
ejection fraction
free survival
electronic health record
basal cell carcinoma
patient reported outcomes
data analysis